JNBA Financial Advisors trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 71.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,731 shares of the company’s stock after selling 26,518 shares during the quarter. JNBA Financial Advisors’ holdings in Johnson & Johnson were worth $1,385,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Reaves W H & Co. Inc. grew its stake in shares of Johnson & Johnson by 45.8% in the fourth quarter. Reaves W H & Co. Inc. now owns 3,500 shares of the company’s stock worth $452,000 after acquiring an additional 1,100 shares during the last quarter. Triad Investment Management acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth $666,000. MERIAN GLOBAL INVESTORS UK Ltd grew its stake in shares of Johnson & Johnson by 8.4% in the fourth quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 199,834 shares of the company’s stock worth $25,788,000 after acquiring an additional 15,514 shares during the last quarter. Valmark Advisers Inc. grew its stake in shares of Johnson & Johnson by 2.1% in the fourth quarter. Valmark Advisers Inc. now owns 6,408 shares of the company’s stock worth $827,000 after acquiring an additional 130 shares during the last quarter. Finally, Guardian Investment Management grew its stake in shares of Johnson & Johnson by 1.0% in the fourth quarter. Guardian Investment Management now owns 30,643 shares of the company’s stock worth $3,954,000 after acquiring an additional 300 shares during the last quarter. 66.85% of the stock is owned by institutional investors and hedge funds.
Several research analysts recently commented on the company. Barclays assumed coverage on Johnson & Johnson in a research report on Friday, June 21st. They issued a “hold” rating and a $140.00 target price for the company. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $157.00 target price (up from $152.00) on shares of Johnson & Johnson in a research report on Monday, May 6th. BMO Capital Markets lifted their price objective on Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a report on Wednesday, April 17th. Goldman Sachs Group assumed coverage on Johnson & Johnson in a report on Tuesday, May 28th. They set a “buy” rating for the company. Finally, Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price objective for the company in a report on Wednesday, March 27th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $149.89.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.07. The firm had revenue of $20.02 billion during the quarter, compared to analyst estimates of $19.55 billion. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The company’s revenue was up .1% on a year-over-year basis. During the same period last year, the company earned $2.06 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 8.6 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 11th. Investors of record on Tuesday, May 28th were given a $0.95 dividend. The ex-dividend date of this dividend was Friday, May 24th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.90. This represents a $3.80 annualized dividend and a dividend yield of 2.73%. Johnson & Johnson’s payout ratio is currently 46.45%.
In other news, Director Marillyn A. Hewson bought 3,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were purchased at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the purchase, the director now owns 3,000 shares of the company’s stock, valued at approximately $419,040. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 0.23% of the stock is currently owned by insiders.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: What is the Quick Ratio?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.